Abcam, ab305302, Anti-IFIT1 antibody [EPR27276-63] (BSA and Azide free)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal IFIT1 antibody. Carrier free. Suitable for IP, Flow Cyt (Intra), ICC/IF, IHC-P, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27276-63,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IP, ICC/IF, Flow Cyt (Intra), WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IFIT1 also known as Interferon-Induced Protein with Tetratricopeptide Repeats 1 is a protein that plays a significant role in antiviral defense mechanisms. It has a molecular mass of approximately 56 kDa. Researchers find IFIT1 predominantly expressed in cells stimulated by interferons. The protein detects viral single-stranded RNA which in turn helps initiate the antiviral response. You will find IFIT1 in various cell types mainly those exposed to viral infections as it is an important part of the body's innate immune system.
Biological function summary
Activities of IFIT1 focus on inhibiting viral replication and translation processes. The protein binds to viral RNAs via its distinctive sensor domains preventing infections from progressing. IFIT1 operates often as part of a larger protein complex with other IFIT family members improving its ability to intercept and inhibit viral RNA. This concerted action provides an important line of defense against diverse viral pathogens by interfering with viral protein synthesis.
Pathways
IFIT1 occupies an important place in the interferon signaling pathways particularly the Jak-STAT pathway. This pathway is critical for mounting antiviral responses when viral infections occur. Through its interactions within the pathway IFIT1 works together with related proteins like IFIT2 and IFIT3 to repel viral threats. By integrating into these pathways it contributes to amplifying the immune response promoting a robust defense system against foreign viral invaders.
IFIT1 is associated mainly with viral diseases such as influenza and hepatitis C. Its role in these diseases involves preventing the communication and replication of the viruses making it a pivotal part of antiviral therapeutic research. Additionally proteins like RIG-I interact with IFIT1 during these processes to recognize viral RNA enhancing the effectiveness of the immune response. These protein partnerships drive ongoing research looking to leverage IFIT1's antiviral properties for treatment developments.